Electroacupuncture for Chemotherapy-induced Peripheral Neuropathy: A Randomized, Controlled Trial

Electroacupuncture for Chemotherapy-induced Peripheral Neuropathy: A Randomized, Patient-Assessor Blinded, Controlled Pilot Clinical Trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0000506

Enrollment

Registered

2012-08-17

Start date

2012-09-04

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : A study that compares treatment efficacy of electroacupuncture VS sham electroacupuncture in the treatment of chemotherapy-induced peripheral neuropathy. Treatment regimen: 2 times/we

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Males and females aged 18 years and older 2. Patients who had received or were currently receiving neurotoxic chemotherapy with a diagnosis of cancer 3. Symptoms of peripheral neuropathy of duration = 1 month attributed to chemotherapy, and a score = 4 out of 10 on the NRS scale. 4. No use of medications to prevent or treat neuropathy within 2 weeks or stable use had been made in their medications to prevent or treat neuropathy within 2 months before screening. 5. ECOG PS of 0-2 6. Life expectancy = 6 months 7. Agreed with written informed consent

Exclusion criteria

Exclusion criteria: 1. Pre-existing or history of peripheral neuropathy due to any cause other than chemotherapy (diabetes, peripheral vascular disease, HIV, alcohol, toxin, hereditary, nerve compression injuries, etc.) 2.Known hypersensitivity reaction after acupuncture treatment or inability to cooperate with acupuncture procedure 3. Received acupuncture, moxibustion, cupping or herbal medicine for peripheral neuropathy last 4 weeks 4. Cardiovascular disorder (e.g. arrhythmia) or using pacemaker 5. Pregnant, expecting pregnant or nursing women 6. Those who are not willing to comply with this study protocol

Design outcomes

Primary

Measure	Time frame
EORTC QLQ-CIPN20	—

Secondary

Measure	Time frame
11-point numerical rating scale (NRS) ;Semmes Weinstein monofilaments test;Nerve Conduction Study;EORTC QLQ-C30;Patient Global Impression of Change (PGIC) ;Adverse events	—

Countries

Korea, Republic of

Contacts

Public ContactJoo-Hee Kim

Korea Institute of Oriental Medicine

Outcome results